Show simple item record

dc.contributor.authorPotter, Brittany L.
dc.contributor.authorMott, Lindsay N.
dc.date.accessioned2021-09-07T18:49:09Z
dc.date.available2021-09-07T18:49:09Z
dc.date.issued2014-04-26
dc.identifier.urihttp://hdl.handle.net/1951/72365
dc.description.abstractMed-tech and pharmaceutical companies have had to implement smart business strategies to respond to changes in the FDA approval processes, introduction of government regulated medical insurance, and new tax and environmental policies. Insurance companies' reimbursement policies are also forcing these companies to reduce pricing. To compensate for these costs, medical device and pharmaceutical companies develop products in the bottom of the pyramid markets that can help world health initiatives, get funding from philanthropic organizations, and be re-marketed in the U.S. with relatively little developmental costs. These companies are also "actively seeking alternative capital sources including government, non-profit foundations, and commercial partners in both developed and emerging countries. ” (Chen, B. p., and Nicholas, C. 2012). This research project reviews these strategies and focuses on pharmaceutical and medical device companies' trending towards philanthropic over normal investors. Key Words: Philanthropy Medical Device Pharmaceutical Alternatives Funding FDA Taxation Reimbursement
dc.language.isoen_US
dc.titleStrategies in the Pharmaceutical and Medical Device Industry (Philanthropy and/or Venture Capitalism)
dc.typeoral
dc.contributor.organizationAlfred University
dc.description.institutionSUNY Brockport
dc.description.publicationtitleMaster's Level Graduate Research Conference
dc.source.statuspublished


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record